MBMichael D. Best

Michael D. Best

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michael D. Best has a total of 106 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A FRET-Based Fluorometric Assay for Tracking the Enzymatic Degradation of Poly- l -Lactic Acid

    by Mahbub Ullah, Jordan A. Cannon, Todd B. Reynolds, Michael D. Best

    Protein engineering has recently emerged as a promising strategy for enhancing the enzymatic recycling of bio-based polymers with the aim of replacing non-degradable petroleum-based plastics with biodegradable ones like poly-l-lactic acid (PLLA). However, a significant challenge exists in the evaluation of the biodegradation efficiency of newly developed enzymes. The precise tracking and continuous rate monitoring of the enzyme-catalyzed hydrolysis remain difficult to achieve with a conventional l-lactate assay kit, which provides only endpoint measurements and is therefore decoupled from the real-time degradation process. To address this issue, we introduce a novel Förster Resonance Energy Transfer (FRET)-based PLLA substrate capable of monitoring real-time PLLA degradation. This was achieved by connecting a highly fluorescent amino carbamoyl coumarin (ACC) dye with a quencher (2,4-dinitrophenyl-l-lysine) via a tetrameric oligo-l-lactate chain. Several fluorescence studies demonstrate that this substrate can effectively detect PLLA-degrading enzyme activity by monitoring increased fluorescence due to enzyme-catalyzed hydrolysis of the oligolactate chain and disruption of the intramolecular FRET system. This substrate can be a potent replacement for the conventional l-lactate assay kit as it allows fast and accurate tracking of the enzyme activity toward PLLA.

  • Cysteine/GSH-Responsive Lipid Switch Development for Liposome Triggered Cargo Release

    by Mahbub Ullah, Kazi R. Shahriar, Mayesha B. Mustafa, Michael D. Best

    Liposomal delivery has emerged as an effective way to transport a broad range of therapeutics due to the excellent biocompatibility of these nanocarriers and their capacity to encapsulate a wide variety of cargo. However, challenges still persist in controlled content release at diseased cells. Although several stimuli have been recently targeted to achieve effective liposomal triggered release at the target site, cysteine and glutathione (GSH), which are overabundant in cancer cells and play crucial roles by deterring oxidative stress and enhancing cell survival offer important targets. Here, we introduce a unique cysteine/GSH-responsive liposomal platform, which was achieved by incorporating a newly developed SLPC lipid containing a disulfide moiety inserted within the sn-2 acyl chain. Förster Resonance Energy Transfer (FRET)-based fluorescence assays, transmission electron microscopy, and dynamic light scattering studies confirmed the formation of stable spherical liposome vesicles containing our SLPC lipid switch and cysteine-responsive controlled cargo release. Selectivity screening with cysteine, GSH, homocysteine, dithiothreitol, methionine, serine, glutathione disulfide (GSSG), alanine, and glutamate demonstrated that SLPC-containing liposomes show a triggered response only in the presence of molecules containing active thiols. These findings demonstrate that SLPC can act as a potent liposomal platform to achieve cysteine/GSH-triggered controlled content release toward the goal of targeted drug delivery to diseased cells.

  • A Synergistic Approach Using a ROS-Responsive Lipid-Based Prodrug for Liposomal Delivery of Doxorubicin

    by Brooke E. Smith, Jinchao Lou, Miranda A. Phillips, Ruhani Sagar, Megan Qualls, Dillon P. McBee, Robert F. Turner, Mahbub Ullah, Joshua A. Baccile, Michael D. Best

    Many clinically used chemotherapeutics, including doxorubicin, suffer from dose-limiting toxicities, poor biodistribution, and limited control over intracellular activation. To mitigate these challenges, two primary delivery strategies have been widely explored: prodrug design and liposomal encapsulation. Prodrugs can improve solubility, pharmacokinetics, and site-selective activation, while liposomes enhance circulation time and reduce off-target exposure. However, each approach presents limitations when employed independently. Prodrugs may introduce stability or solubility concerns and can undergo premature activation, whereas liposomal formulations often rely on passive release mechanisms and may exhibit incomplete or non-specific cargo leakage. In the current work, we sought to develop a synergistic delivery approach that integrates a chemically responsive prodrug directly within the liposomal membrane that responds to reactive oxygen species (ROS) highly upregulated within diseased cells. We report a ROS-responsive doxorubicin lipid prodrug conjugate, ROSDoxL, which is incorporated within the liposomal bilayer, enabling membrane-embedded therapeutic loading rather than aqueous core encapsulation. The prodrug design features a boronate caging group that undergoes oxidation in the presence of elevated reactive oxygen species, triggering a self-immolative release of doxorubicin. A non-responsive control doxorubicin lipid, DoxL, lacking the boronate moiety, was used to evaluate the specific ROS-mediated uncaging mechanism. ESI-HRMS studies confirmed ROS-dependent cleavage of ROSDoxL, while liposomal characterization and cellular studies demonstrated functional delivery and concentration-dependent cytotoxicity in A375 melanoma cells comparable to free doxorubicin. Our membrane-integrated liposomal prodrug approach provides a modular strategy for coupling disease-associated biochemical signals to controlled drug activation, advancing liposomal systems beyond passive carriers towards stimulus-responsive therapeutic delivery.

  • Recent Advancements in Phospholipid Metabolic Labeling Using Clickable Probes

    by Robert J. Maraski, Michael D. Best

    Herein, we present a perspective on recent advancements in the field of metabolic labeling as a method for interrogating phospholipids in terms of their biosynthesis, trafficking, and localization. Phospholipids are crucial for establishing cell morphology and signaling processes mediated by interactions between nearly all relevant cellular substrates. Bioorthogonal chemistry has provided a convenient platform in which clickable probes that mimic biologically active precursors are deployed to generate labeled versions of phospholipids in cells, enabling the study of downstream lipid activities without affecting cell viability. The introduction of a clickable handle onto precursor analogs enables varied postderivatization techniques such as visualization with fluorescence microscopy, enhancement of mass spectrometric detection, as well as enrichment and identification following biotinylation, just to name a few. In this perspective, we outline how the sum of these studies has provided a strong chemical toolbox for investigating lipid interactions and functions within a cellular environment, enabling a deeper understanding of these indispensable biomolecules.

  • Open Access

    Metabolic Labeling of Phosphatidylethanolamine Lipids in Cells Using Clickable Ethanolamine Analogs

    by Robert J. Maraski, Jinchao Lou, Todd B. Reynolds, Michael D. Best

    Phosphatidylethanolamine (PE) is the second most abundant phospholipid in mammalian cells. The cone‐shaped structure of PE positions this lipid to act as a cornerstone of signaling events, such as those involving protein–protein and lipid–protein interactions, as it has been shown to promote conformational changes in both protein and lipid‐based membrane structures. Despite this importance, chemical tools to interrogate the biological activity and trafficking of PE lipids are limited. Herein, we report the development of ethanolamine probes functionalized with clickable tags that are capable of infiltrating native cellular pathways and subsequently producing labeled PE lipids. Derivatization of click‐tagged PE products enabled fluorescence microscopy imaging of these lipids in cells. Interrogation of the efficacy of these probes for biological incorporation was conducted using mass spectrometry and thin‐layer chromatography analysis to identify various species of tagged PE molecules. This approach provides an invaluable step toward metabolic labeling strategies that will aid in the tracking of PE biosynthesis and trafficking pathways in cells.


  • De Novo Lipid Switch Design for Reactive Oxygen Species-Triggered Liposomal Release

    by Kazi R. Shahriar, Mayesha B. Mustafa, Nathan R. Kaufman, Michael D. Best

    Liposomal nanocarriers are highly effective for drug delivery, since they shield encapsulated therapeutic cargo and enhance cellular infiltration. However, a drawback of liposomal carriers involves the limited release of contents after delivery. As such, stimulus-responsive liposomes harnessing synthetic lipid switches that trigger cargo release upon encountering disease-associated conditions have the potential to address this issue. Reactive oxygen species (ROS) have emerged as prominent target stimuli because of their upregulation in diseased cells. Lipid switches designed for liposome release are often derived from phospholipid precursors, an approach that suffers from high expense and hinders scalability because of the limited availability of phospholipids. To address this issue, we report the design and synthesis of an ROS-responsive lipid switch from first principles that does not utilize phospholipid precursors. This culminated in a scalable nonphospholipid switch that forms stable liposomes yet undergoes clean, H2O2-triggered degradation under aqueous oxidative conditions. Using Nile Red release, ANTS–DPX dequenching, and dynamic light scattering (DLS) experiments, we show that liposomes containing lipid switch 4 exhibit minimal basal leakage and maintain structural integrity, while H2O2 induces dose-dependent membrane permeabilization with characteristic changes in vesicle size. We also show that liposomes containing 4 demonstrate superior and more consistent results compared with those containing 6, which have longer acyl chains. PC-only negative controls display no comparable response, confirming that release arises from selective boronate oxidation rather than nonspecific degradation. These results highlight the potential of a synthetically accessible, modular nonphospholipid architecture for stimulus-responsive triggered release as a practical platform for redox-responsive therapeutic delivery.

  • Enhancing Triggered Release of Polar Cargo from ROS-Responsive Liposomes

    by Annaleena Hansen, Mayesha B. Mustafa, Jinchao Lou, Michael D. Best

    Liposomes are promising nanocarriers because of their ability to encapsulate and deliver therapeutic cargo with wide-ranging physicochemical properties. However, liposome delivery could be improved by enhancing triggered release of cargo and particularly doing so in a manner that is selective toward diseased cells. Reactive oxygen species (ROS) provide exciting targets to explore as triggers for the development of stimuli-responsive liposomes due to substantial differences in ROS abundance between diseased versus healthy cells. While our group previously reported ROS-responsive liposomes using a synthetic lipid switch, polar cargo release was slow and limited using our original platform. Herein, we report an improved ROS-responsive lipid switch (2) containing an ROS-responsive boronate ester headgroup attached using an advanced self-immolative linker (SIL) bearing an electron-donating methoxy substituent to a lipid scaffold. Both hydrophobic and hydrophilic fluorescence-based dye release assays showed that liposome formulations including lipid switch 2 were initially stable but successfully released cargo when treated with hydrogen peroxide. Furthermore, dynamic light scattering (DLS) analysis was used to characterize changes in the size and dispersity of liposomes before and after treatment. Ultimately, lipid 2 enabled dramatically faster polar dye cargo release at a lower percentage of incorporation compared to our initial lipid switch. Such improvements increase the prospects of ROS-responsive liposomes for delivery applications.

  • Open Access

    Therapeutic Improvement in People With Schizophrenia Undergoing tACS/CBTp (Transcranial Alternating Current Stimulation/Cognitive Behavioral Therapy for Psychosis) Associated With Usual Medication Regimen: Protocol for a Pilot, Randomized, Single-Blind Trial

    by Felicia Iftene, Adriana Farcas, Simon O'BRien, Christopher Bowie, Michael Best, Oyedeji Ayonrinde, Terry Landry, Jennifer Carlson, Scott John Davidson, Ellie Rodgerson, et al.

    Background: Transcranial alternating current stimulation (tACS) applies a low-intensity sinusoidal electrical current through electrodes placed on the scalp to boost the brain’s own oscillation by way of entrainment. When a single frequency is applied, this exogenous oscillation synchronizes with the brain’s endogenous frequency. Gamma frequency synchrony stands out as a binding mechanism for integrating disparate brain networks, mediating perception, cognition, and memory, typically disturbed in schizophrenia. The treatment of schizophrenia includes medication and cognitive behavioral therapy for psychosis (CBTp). We are adding tACS to these usual treatments, targeting gamma oscillation stimulation, to augment the CBTp efficacy in people living with schizophrenia. Objective: This study aims to elicit cognitive readiness and therapeutic engagement by adding tACS to each CBTp session in individuals with schizophrenia taking their usual medication, to evaluate the possible improvement of the level of functioning, and to determine if the response to intervention is gender specific. Methods: This is a pilot, prospective, randomized, repeated-measures, single-blind study design. We expect to enroll 28 participants randomly assigned to one of two treatment arms: arm 1 (tACS/CBTp, n=14) or arm 2 (sham tACS/CBTp, n=14; tACS is sham, but CBTp is active). The intervention with active or sham tACS/CBTp will take place weekly for 16 weeks. Primary outcome measures—electroencephalogram, Positive and Negative Syndrome Scale, 16-item Negative Symptom Assessment, and Cognitive Flexibility Scale—will evaluate the efficacy of treatment at the end of the intervention and at the two follow-ups. We will use SPSS (version 29, IBM Corp); the main tests will include repeated measures and mixed design ANOVA. Results: The timeline for recruitment, treatment, and follow-ups is 18 months, followed by 6 months for data analysis, writing manuscripts, and dissemination activities. By November 1, 2025, we have enrolled 15 participants: 12 are following the intervention protocol (8 active and 4 sham tACS). Two participants were screening failures, and one participant withdrew after intervention 2. Conclusions: Our expectations are as follows. CBTp will improve the scores of psychological and psychosocial tests at the end of therapy for both groups, but it will be superior for the group with tACS intervention. Considering that cognitive and emotional status is gender dependent (hormonal differences, brain structure, and sociocultural influences), we expect that the therapeutic response could be gender specific. CBTp will enhance electroencephalogram activity and the heart in clients with schizophrenia at the end of therapy for both groups, but it will be superior for the group with tACS preintervention. The baseline heart rate variability will predict symptom improvement and will increase over the course of therapy. We hope our research will improve the treatment of people living with schizophrenia, thereby enhancing their quality of life, reducing the rate of relapse, and lowering the costs of care. Trial Registration: ClinicalTrials.gov NCT06889025; https://clinicaltrials.gov/study/NCT06889025 International Registered Report Identifier (IRRID): PRR1-10.2196/80593

  • Open Access

    Engineering tunable GTP/TPi-responsive liposomes through liposomal membrane modulation using a bis-triphenylphosphonium lipid switch

    by Brooke E. Smith, Caleb G. Russell, Mayesha B. Mustafa, Michael D. Best

    Liposomes incorporating a bis-phosphonium lipid switch exhibit tunable cargo release triggered by GTP or TPi. Modulating lipid ratios within the liposome controls metabolite selectivity and release kinetics for responsive cargo delivery.


  • Metabolic labeling of glycerophospholipids

    by Robert J. Maraski, Christelle F. Ancajas, Jinchao Lou, Michael D. Best